Sorrento Therapeutics, Inc. (SRNE)

Trade SRNE now with
1/22/2019 7:07:19 AM Sorrento Therapeutics Announces Interim Results In Osteoarthritis Knee Pain Phase 1b Trial Of Resiniferatoxin
1/14/2019 7:09:42 AM Scilex Reports Addition Of ZTlido To Express Scripts National Formularies
11/1/2018 7:24:54 AM Sorrento Therapeutics Begins Dosing In Anti-CD38 CAR-T Phase 1 Clinical Study For R/r Multiple Myeloma
9/10/2018 4:01:37 AM Sorrento Therapeutics Subsidiary, Scilex, Raises $140 Mln In Non-Dilutive Royalty-Based Financing
8/13/2018 4:01:56 AM Sorrento Therapeutics Says Sorrento Resiniferatoxin Phase 1B Trial Meets Both Safety And Efficacy Expectations
7/3/2018 9:31:58 AM Sorrento Therapeutics Acquires Sofusa Lymphatic Delivery Platform For Immune-Oncology Antibody Therapeutics
3/28/2018 9:34:11 PM Sorrento Therapeutics CEO Says Confident Of Executing Strategic Plan
3/27/2018 8:06:08 AM Sorrento Therapeutics Announces Unsecured $120.5 Mln Convertible Note Financing
3/19/2018 8:14:21 AM Sorrento Therapeutics Appoints Jiong Shao As EVP And CFO
3/5/2018 9:22:13 AM New Drugs Approved In February
1/24/2018 8:16:28 AM Sorrento Therapeutics Announces Expansion Of Its GMP CAR-T Manufacturing Capacity
12/22/2015 8:34:03 AM FBR Capital Markets Initiates Sorrento Therapeutics, Inc. (SRNE) At Outperform With $22 Price Target